News
Article
Author(s):
We've compiled all our coverage from the biggest dermatology meeting of the year to give you a thorough recap of everything you need to know or catch up on.
Yesterday was the conclusion of the eventful 2024 American Academy of Dermatology (AAD) Annual Meeting. Dermatology Times editors were on site in San Diego for all 5 days of the CME conference providing you with the latest updates live from the conference floor.
In total, we spoke with nearly 40 different experts in dermatology. We covered several late-breaking clinical research updates, award-winning poster presentations, and provided detailed insights from numerous conference sessions.
Not only did we cover the AAD's annual meeting, but we also provided coverage and insights from 2 meetings hosted in conjunction: the 20th Annual Skin of Color Society (SOCS) Scientific Symposium and the 36th Annual Pre-AAD Meeting of the Society for Pediatric Dermatology.
With so much to unpack (from the meeting and from suitcases, of course), we have compiled our coverage into a comprehensive recap to provide you with an overview of everything you missed or need to know.
The American Acne and Rosacea Society welcomed Del Rosso as its new president and he shared key takeaways from his AAD sessions.
Gallo presented pearls on the pathophysiology of acne and how newer studies have changed acne treatment methodologies.
Naiem Issa, MD, PhD, emphasized the importance of increased awareness regarding antibiotic stewardship among dermatologists, as well as the recently updated acne guidelines.
Discover the science behind cosmeceutical advancements and the importance of staying informed for enhanced patient care with Zoe Diana Draelos, MD.
The injectable polidocanol exhibited high efficacy, quicker onset of benefit, reduced downtime, and fewer side effects lasting longer than 30 days.
Waibel shared pearls in laser therapy and other scar treatment modalities in her talks at AAD.
Frey discussed the role of various cosmeceuticals and ingredients in benefitting the skin health of patients, as well as insights into pairing OTC products with Rx.
New data was presented at the American Academy of Dermatology Annual Meeting in San Diego, California.
The international observational study aims to understand how moderate to severe AD affects children under 12 years of age, particularly in terms of height, weight, and BMI.
Melinda Gooderham, MSc, MD, FRCPC, provided insights into the significance of the DELTA 3 extension data presented at AAD 2024.
Menes Kizoulis shared key highlights from the research conducted alongside leading dermatologists, like Alan Irvine, MD, DSc, and Patricia Farris, MD, MS.
The third-place poster provided insights into the safety profile of JAK inhibitors.
Founder Dina El-Sherif, MBA, gave an in-depth overview of the at-home facial rejuvenation device and its 3-step process at AAD 2024.
The 20th Annual Skin of Color Society Scientific Symposium featured diverse research including studies on traction alopecia among individuals with religious head coverings, challenges in color-matching universal tinted sunscreens, dermatologic disparities in American Indian/Alaskan Native populations, and more.
"We cannot do health equity outside of an institution unless we figure out how to get our own house in order," the AMA leader said.
A vote during the annual meeting will keep DEI initiatives in place and members are awaiting news on what those initiatives will look like.
The Bristol Myers Squibb-hosted event brought together a panel of leading women in dermatology to discuss the challenges they've faced and how women can support each other.
The poster shares results form consensus research on using LODM for hair loss.
Ronda Farah, MD, FAAD, reviews top hair loss pearls from her 5 sessions at AAD 2024.
How can you improve excision care for your patients with hidradenitis suppurativa? Ashley Nicole Elsensohn, MD, MPH, FAAD, shared clinical pearls at the AAD Annual Meeting.
Alexandra Kimball, MD, FAAD, reviews late-breaking data at AAD on lutikizumab for hidradenitis suppurativa.
The phase 3 studies, BE HEARD I and BE HEARD II, showed significant improvements in skin pain over the 48-week period.
Maria Aleshin, MD, FAAD, presented surgical procedures for HS that can be performed in the office.
Furthermore, prenatal exposure to hyperandrogenism, a hormonal imbalance characteristic of HS, may influence the health outcomes of boys and girls differently.
Joseph Zabinski, PhD, MEM, of OM1, shares insights at AAD into how artificial intelligence can mature and be a positive tool for disease detection.
Jenny Murase, MD, said the average dermatologist manages 2-3 patients with delusional infestations every 5 years. Learn what to expect and how to manage it with empathy.
Christopher Bunick, MD, PhD, presented updates and new data on the recent news of benzene found in benzoyl peroxide products.
Christopher Bunick, MD, PhD, provides tips for the general dermatologist to treat ichthyosis and shares data on TMB-001 in development for ichthyosis.
The congenital ichthyosis session the 2024 AAD Annual Meeting covered real-world patient cases and treatments on the horizon.
Lio delves into his American Academy of Dermatology Annual Meeting session, "Dietary Triggers and Modifications of Common Dermatologic Conditions: An Evidence Based Approach."
In addition to recapping key highlights from his session, Friedman discusses what is new or upcoming in dermatology that most excites him.
Raj Chovatiya, MD, PhD, delved into the conditions that could be red, itchy, and not atopic dermatitis. He explained the importance of knowing characteristics for various inflammatory conditions.
Kim, who received the Marion B. Sulzberger Award at the 2024 American Academy of Dermatology Annual Meeting, discussed itch research an implications for clinical practice.
Chovatiya acknowledged the common sentiment among residents who, despite dedicating significant time to studying and working during residency, may feel unprepared.
Jason S. Reichenberg, MD, MBA, FAAD, shares tips for improving interactions and communications at the 2024 AAD Annual Meeting.
Dermatologists are able to connect pediatric patients to psychology clinicians for multidisciplinary care under one roof.
In an exclusive interview with Gary Dudzik, he shared top 5 considerations dermatology clinicians should have when choosing financial services for their practices and overall financial goals.
Lio discussed his sessions at AAD, including addressing systemic malignancies with alternative or adjunctive therapies and the importance of minimizing pain in dermatology procedures.
Kelly M. Cordoro, MD, shared tips on implementing shared decision making in pediatric dermatology dermatology at the annual conference.
April W. Armstrong, MD, MPH, shared treatment insights with attendees at the 36th Annual Pre-AAD Meeting of the Society for Pediatric Dermatology.
Eichenfield discusses the late-breaking data on roflumilast cream 0.05% in the pediatric patient population and its implications.
Burnett recently spoke with Dermatology Times to discuss the background, methods, and findings of the late-breaking INTEGUMENT-PED data, as well as its potential real-world and clinical implications.
Swanson shared updates: a look ahead and what's in store for pediatric dermatology.
In between sessions, Lal shared his favorite pearls from AAD, a recent challenging pediatric case in his practice, the significance of LinkedIn, and more.
Maggi Ahmed, MD, PhD, demonstrated superior pigmentation outcomes and reduced CD8+ T cell numbers in her recent research results.
Iltefat Hamzavi, MD, reviews late-breaking data at AAD on upadacitinib as monotherapy.
Arianne Shadi Kourosh, MD, MPH, FAAD, shared pearls on environmental factors that can impact skin aging and pigmentation including visible light, IR radiation, location, and pollution.
Shawn Kwatra, MD, presented late-breaking data at AAD 2024 on the largest prurigo nodularis and nemolizumab clinical trial, OLYMPIA.
Shawn Kwatra, MD, shared positive updates on phase 2 oral povorcitinib for prurigo nodularis.
In an AAD late-breaking research session, Joel Gelfand, MD, MSCE, FAAD, presented in-depth results of the LITE Study.
Lloyd Miller, MD, PhD, delves into the new data demonstrating high rates of skin clearance over 52 weeks in adults with moderate to severe plaque psoriasis.
Mona Shahriari, MD, presented real-world data on the efficacy of IL-23 inhibitors for psoriasis, as well as shared her advice from the Bristol Myers Squibb Women's Connection Forum.
Rebecca Hartman, MD, MPH, FAAD, and Christine Kannler, MD, FAAD, took a deep dive into considerations and pearls to treat patients who have been exposed to extreme heat and chemicals in the line of duty.
To keep up to date with future conference coverage updates, be sure to subscribe to Dermatology Times eNewsletters.